Advertisement

Clindamycin Injection

[15 August 2014]

Products Affected - Description

Clindamycin injection, Fresenius Kabi (formerly APP)
150 mg/mL, 60 mL bulk vial (NDC 63323-0282-60)
 
Clindamycin injection, Hospira
150 mg/mL, 2 mL ADD-Vantage vials (NDC 00409-4053-03)
150 mg/mL, 4 mL ADD-Vantage vials (NDC 00409-4054-03)
150 mg/mL, 6 mL ADD-Vantage vials (NDC 00409-4055-03)

Cleocin injection, Pfizer
150 mg/mL, 4 mL ADD-Vantage vials (NDC 00009-3124-03)
150 mg/mL, 6 mL ADD-Vantage vials (NDC 00009-3447-03)
 
Clindamycin injection, Sagent
150 mg/mL, 4 mL vial (NDC 25021-0115-04)
150 mg/mL, 60 mL bulk vial (NDC 25021-0115-51)
 
Clindamycin injection, Sandoz
600 mg/50 mL premix vials (NDC 00781-3289-09)
900 mg/50 mL premix vials (NDC 00781-3290-09)

Reason for the Shortage

  • Pfizer states the Cleocin Add-Vantage vials are on shortage due to manufacturing delays.
  • Hospira has clindamycin injection on shortage due to manufacturing delays.
  • Akorn launched clindamycin injection in June 2013.
  • Sandoz had clindamycin injection on shortage due to increased demand.
  • Sagent has clindamycin injection on shortage due to manufacturing delays.

Available Products

Clindamycin injection, Akorn
300 mg/50 mL premix vials (NDC 17478-0120-50)
600 mg/50 mL premix vials (NDC 17478-0121-50)
900 mg/50 mL premix vials (NDC 17478-0122-50)
 
Clindamycin injection, Fresenius Kabi (formerly APP)
150 mg/mL, 2 mL vial (NDC 63323-0282-02)
150 mg/mL, 4 mL vial (NDC 63323-0282-04)
150 mg/mL, 6 mL vial (NDC 63323-0282-06)

Clindamycin injection, Hospira
150 mg/mL, 2 mL vial (00409-4050-01)
150 mg/mL, 4 mL vial (00409-4051-01)
150 mg/mL, 6 mL vial (00409-4052-01)
150 mg/mL, 60 mL bulk vial (NDC 00409-4197-01)
 
Clindamycin injection, Sagent
150 mg/mL, 2 mL vial (NDC 25021-0115-02)
150 mg/mL, 6 mL vial (NDC 25021-0115-06)

Cleocin injection, Pfizer
150 mg/mL, 2 mL vial (NDC 00009-0870-26)
150 mg/mL, 4 mL vial (NDC 00009-0775-26)
150 mg/mL, 6 mL vial (NDC 00009-0902-18)
150 mg/mL, 60 mL vial (NDC 00009-0728-09)
300 mg/50 mL premix bags (NDC 00009-3381-02)
600 mg/50 mL premix bags (NDC 00009-3375-02)
900 mg/50 mL premix bags (NDC 00009-3382-02)
 
Clindamycin injection, Sandoz
300 mg/50 mL premix vials (NDC 00781-3288-09)

Estimated Resupply Dates

  • Fresenius Kabi has clindamycin 150 mg/mL 60 mL bulk vials on allocation.
  • Hospira has clindamycin 150 mg/mL 4 mL ADD-Vantage vials and 150 mg/mL 6 mL ADD-Vantage vials on back order with an estimated release date of August 2014. The 150 mg/mL 2 mL ADD-Vantage vials are on back order with an estimated release date of September 2014.
  • Pfizer has Cleocin 150 mg/mL 4 mL and 6 mL ADD-Vantage vials on back order and the company estimates a release date of September 2015.
  • Sagent has clindamycin 4 mL vials and 60 mL bulk vials on back order and the company cannot estimate a release date.
  • Sandoz has clindamycin 600 mg/50 mL premixed vials on back order and the company estimates a release date in late-August 2014. Clindamycin 900 mg/50 mL premixed vials are on intermittent back order and the company is releasing supplies as they become available. 

Related Shortages

Updated

August 15, 2014; August 8, 2014; July 8, 2014; June 12, 2014; May 23, 2014; May 5, 2014; April 23, 2014; April 7, 2014; March 26, 2014; March 11, 2014; March 5, 2014; February 21, 2014; February 10, 2014; January 24, 2014; January 14, 2014; December 27, 2013; December 18, 2013; November 21, 2013; November 6, 2013; October 23, 2013; October 14, 2013; October 7, 2013; September 17, 2013; August 28, 2013; August 7, 2013; July 3, 2013; June 3, 2014, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement